These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34364162)

  • 21. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hormone therapy and breast cancer].
    de Cremoux P
    Bull Cancer; 2011 Nov; 98(11):1311-9. PubMed ID: 22020743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine therapy for breast cancer: an overview.
    Cheung KL
    Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in computational design of potent aromatase inhibitors: open-eye on endocrine-resistant breast cancers.
    Spinello A; Ritacco I; Magistrato A
    Expert Opin Drug Discov; 2019 Oct; 14(10):1065-1076. PubMed ID: 31339372
    [No Abstract]   [Full Text] [Related]  

  • 27. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
    Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
    J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
    Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
    J Med Chem; 2024 Jun; 67(11):8913-8931. PubMed ID: 38809993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
    Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
    Xiong S; Song K; Xiang H; Luo G
    Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
    Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
    Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
    McDonnell DP; Wardell SE; Norris JD
    J Med Chem; 2015 Jun; 58(12):4883-7. PubMed ID: 26039356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of breast cancer: current state of the science and future opportunities.
    Uray IP; Brown PH
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?
    Johnston SR
    Breast Cancer Res; 2005; 7(3):119-30. PubMed ID: 15987442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.